A novel class of antibiotics to combat Antimicrobial Resistance

Project description

Novel peptide-based antibiotics against drug-resistant bacteria

Israel-based Omnix Medical is developing novel antibiotic agents for the treatment of infections caused by drug-resistant bacteria. The company’s proprietary platform technology is changing the biodegradability of antimicrobial peptides, creating a new class of antibiotics with a unique mechanism of action, which is effective regardless of underlying resistance patterns. The goal of the EU-funded OMN6 project is to demonstrate clinical safety and efficacy in the treatment of deadly nosocomial Acinetobacter baumannii infections. To that end, it will support Omnix Medical in the commercialisation of its lead antibiotic candidate, which has already made it past the proof-of-concept stage.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• medical and health sciences › basic medicine › medicinal chemistry
• natural sciences › biological sciences › biochemistry › biomolecules
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › antibiotics
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › antibiotic resistance

Programme(s)

• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020-3
See other projects for this call

Funding Scheme

SME-2b - SME Instrument (grant only and blended finance)

Coordinator

OMNIX MEDICAL LTD

Address

Racah 1
9270401 Jerusalem
Israel

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

EU contribution

€ 2 389 674,70